While direct head-to-head clinical trials comparing telmisartan to losartan are limited, available literature suggests telmisartan may provide more sustained blood pressure control. A meta-analysis of 15 randomized controlled trials revealed that telmisartan is associated with greater efficacy in reducing systolic and diastolic blood pressure compared to losartan, with a more pronounced effect observed among Asian populations. Due to its longer half-life, telmisartan was consistently preferre...
A 2022 meta-analysis of 15 randomized controlled trials involving 1,926 subjects with mild to moderate essential hypertension assessed the comparative efficacy of telmisartan and losartan. The trials included varied designs, such as double-blinded, open-label, and crossover studies, carried out in diverse geographic regions, including Asia, Europe, and the Americas. Blood pressure outcomes, specifically systolic (SBP) and diastolic (DBP) pressure reduction, were measured and analyzed using a random-effects model. Statistical heterogeneity was assessed, and meta-regression analysis explored potential sources of heterogeneity across variables such as ethnicity, age, and gender. The analysis revealed that telmisartan demonstrated superior efficacy in lowering both SBP (weighted mean difference of 2.69 mm Hg, 95% confidence interval [CI] 1.38 to 4.00) and DBP (weighted mean difference of 1.26 mm Hg, 95% CI 0.45 to 2.08) compared to losartan. Subgroup analysis indicated a more pronounced...
READ MORE→
A search of the published medical literature revealed
4 studies investigating the researchable question:
When is telmisartan preferred over losartan?
Level of evidence
A - Multiple high-quality studies with consistent results
READ MORE→
[1] Kumari K, Toppo MS, Majhi L, Kumar A. Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis. J Family Med Prim Care. 2022;11(10):6227-6235. doi:10.4103/jfmpc.jfmpc_787_22
[2] Zhang Z, Yang H, Guo H. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis. Int J Clin Pharm. 2024;46(5):1034-1043. doi:10.1007/s11096-024-01755-5
[3] Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T; All-Literature Investigation of Cardiovascular Evidence...